Approval · Notice of Compliance 15626 · 2014
INVOKANA: Notice of Compliance 15626
Issued May 23, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 15626
- Date
- May 23, 2014
- Company
- Janssen Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Oral antihyperglycaemic agent
Products in this notice
Medicinal ingredients
- CANAGLIFLOZIN 100 MG per TAB
- CANAGLIFLOZIN 300 MG per TAB